Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | KLK1 | P06870 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | STAMBP | O95630 | 1/20 | 0.40 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328501 | 0.86 | KMT2A (0.50) | KMT2AMEN1EGFRCDK2PPARG | |
| SCHEMBL15328515 | 0.86 | KMT2A (0.42) | KMT2AMEN1THRBHPGDF2 | |
| SCHEMBL15328621 | 0.85 | KMT2A (0.51) | KMT2AMEN1EGFRCDK2PPARG | |
| SCHEMBL15328404 | 0.84 | SRC (0.49) | PPARGLMNATHRBKLKB1KLK1 | |
| SCHEMBL15328443 | 0.83 | KMT2A (0.47) | KMT2AMEN1EGFRCDK2PPARG | |
| SCHEMBL15733200 | 0.83 | KDM4E (0.48) | KMT2AMEN1RXFP1LMNATP53 | |
| SCHEMBL15328143 | 0.83 | MEN1 (0.47) | KMT2AMEN1PPARGRXFP1LMNA | |
| SCHEMBL15328321 | 0.83 | DDR1 (0.51) | KMT2AMEN1PPARGRXFP1LMNA | |
| SCHEMBL15328395 | 0.82 | KMT2A (0.48) | KMT2AMEN1EGFRCDK2PPARG | |
| SCHEMBL15328430 | 0.82 | KMT2A (0.48) | KMT2AMEN1EGFRCDK2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | claimed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | claimed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | claimed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | claimed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| US-9108936-B2 | Substituted 4-aminobenzamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2015-08-18 | — | — | US | disclosed |
| EP-2844645-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2015-03-11 | — | — | EP | disclosed |
| WO-2013156155-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | GRUENENTHAL GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281452-A1 | SUBSTITUTED 4-AMINOBENZAMIDES AS KCNQ2/3 MODULATORS | KCNJ2, KCNQ2, KCNQ1 | KMT2A 196/4885MEN1 4108/4885EGFR 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.